Showing results (61-70 of 2,355) with videos related to

Sort By:
Pageof 236
Clinical Neuropharmacology|February 13, 2018
Allergy to CarbidopaMariana Aurora Cansino-Torres, Valeria Sandoval-Rodríguez, Michel Sáenz-Farret, et al.
Clinical Neuropharmacology|October 19, 2017
Inhaled Loxapine for Agitation in Intoxicated Patients: A Case SeriesCarlos Roncero, Elena Ros-Cucurull, Raúl Felipe Palma-Álvarez, et al.
Clinical Neuropharmacology|June 1, 1987
Drug levels and antiparkinsonian drugs in neuroleptic-treated schizophrenic patientsA Hitri, R B Craft, R Sethi, et al.
Clinical Neuropharmacology|September 9, 2006
Levetiracetam in tardive dyskinesiaGiuseppe Meco, Edito Fabrizio, Antonio Epifanio, et al.
Clinical Neuropharmacology|September 9, 2006
Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performanceBart Scholtissen, Frans R J Verhey, Jos J Adam, et al.
Clinical Neuropharmacology|November 11, 2006
Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label studyFilippo Brighina, Antonio Palermo, Antonina Aloisio, et al.
Clinical Neuropharmacology|November 11, 2006
Treatment of primary writing tremor with botulinum toxin type a injections: report of a case seriesSpiridon Papapetropoulos, Carlos Singer
Clinical Neuropharmacology|August 1, 1991
Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotensionA Cavallini, G Micieli, E Martignoni, et al.
Clinical Neuropharmacology|June 15, 2006
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primatesLance A Smith, Michael J Jackson, Louisa Johnston, et al.
Clinical Neuropharmacology|June 15, 2006
A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophreniaMassimo Carlo Mauri, Alessandro Colasanti, Matteo Rossattini, et al.
Pageof 236